Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 72 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Stomach Ulcer Clear all
Completed No phase listed Observational

Proton Pump Inhibitor (PPI) Therapy for Newly Diagnosed Esophagitis

NCT00586963
View directory record Official record
Conditions
Erosive Esophagitis, Reflux Esophagitis, GERD
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 23, 2010 · Synced Oct 21, 2026, 2:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers

NCT00325715
View directory record Official record
Conditions
Peptic Ulcer
Interventions
AGN 201904, esomeprazole
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2011 · Synced Oct 21, 2026, 2:57 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Metoclopramide in Upper Gastrointestinal Bleed

NCT05746377
View directory record Official record
Conditions
Upper GI Bleeding, Bleeds Gastric, Bleed Ulcer, Hemorrhage Gastric, Hemorrhage; Ulcer
Interventions
Metoclopramide 10mg, Saline
Drug
Lead sponsor
Mercy Health System
Network
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rockford, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 21, 2026, 2:57 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis

NCT00255151
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
100
States / cities
Anniston, Alabama • Hueytown, Alabama • Huntsville, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 21, 2026, 2:57 PM EDT
Completed Not applicable Interventional Results available

MAGNET (Magnetically Controlled Capsule for Assessment of Gastric Mucosa in Symptomatic Patients)

NCT04724291
View directory record Official record
Conditions
Abdominal Pain, Gastritis, Gastric Ulcer, Gastric Cancer
Interventions
MAGNET
Device
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 21, 2026, 2:57 PM EDT
Terminated No phase listed Observational

Systems Biology of Gastrointestinal and Related Diseases

NCT05579444
View directory record Official record
Conditions
Ulcerative Colitis, Crohn Disease, Obesity, Colon Polyp, Eosinophilic Esophagitis, GERD, Gastro Esophageal Reflux, Barrett Esophagus, Esophageal Cancer, Gastritis, Gastric Ulcer, Duodenal Ulcer, Intestinal Metaplasia, Gastric Cancer, Lymphocytic Colitis, Microscopic Colitis, Celiac Sprue, IBS, Irritable Bowel Syndrome, SIBO, NAFLD, Gallstone Disease
Interventions
Not listed
Lead sponsor
Viome
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 21, 2026, 2:57 PM EDT
Completed Phase 2 Interventional Results available

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

NCT00454363
View directory record Official record
Conditions
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Multiple Endocrine Neoplasia Type 1, Pancreatic Glucagonoma, Pancreatic Insulinoma, Pancreatic Polypeptide Tumor, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Pancreatic Neuroendocrine Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Somatostatin-Producing Neuroendocrine Tumor
Interventions
Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
21 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
3
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 21, 2026, 2:57 PM EDT
Completed Phase 4 Interventional

Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease

NCT03667703
View directory record Official record
Conditions
Congenital Heart Disease, Upper Gastrointestinal Bleeding, Stress Ulcer, Infection
Interventions
Famotidine, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Minute to 12 Months
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 21, 2026, 2:57 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas

NCT00001165
View directory record Official record
Conditions
Islet Cell Adenoma, Neoplasm Metastasis, Zollinger Ellison Syndrome
Interventions
combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1978 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 2:57 PM EDT
Completed Phase 4 Interventional

An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium

NCT00428701
View directory record Official record
Conditions
Gastric Ulcer
Interventions
Esomeprazole Sodium
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
5
States / cities
Newark, Delaware • Shreveport, Louisiana • Hershey, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Oct 21, 2026, 2:57 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

NCT00251693
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Lansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
2,038 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
96
States / cities
Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 93 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 21, 2026, 2:57 PM EDT
Recruiting Not applicable Interventional

Marginal Ulcer Healing With Low-Thermal Argon Plasma Endoscopic Treatment

NCT06543316
View directory record Official record
Conditions
Roux-en-y Anastomosis Site, Marginal Ulcer, Marginal Ulcer (Peptic) or Erosion, Ulcer, Ulcer, Gastric, Ulcer Gastrointestinal, Abdominal Pain, Nausea, Vomiting, GastroIntestinal Bleeding, Dysphagia, Ulcer Gastrojejunal
Interventions
Low Thermal Plasma (LTP) Treatment, Standard of Care Ulcer Treatment (typically PPI Administration)
Procedure · Other
Lead sponsor
Christopher C. Thompson, MD, MSc
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 21, 2026, 2:57 PM EDT
Completed Phase 2 Interventional

Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer

NCT00001228
View directory record Official record
Conditions
Islet Cell Adenoma, Zollinger Ellison Syndrome
Interventions
Interferon
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1988 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 2:57 PM EDT
Completed Phase 2 Interventional

The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid

NCT00001191
View directory record Official record
Conditions
Gastrinoma, Zollinger Ellison Syndrome
Interventions
Pantoprazole, Omeprazole
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1983 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 2:57 PM EDT
Terminated Phase 4 Interventional

Lansoprazole Preventing Gastroduodenal Stress Ulcerations

NCT00220909
View directory record Official record
Conditions
Patients Undergoing Elective Coronary Artery Bypass Graft
Interventions
Lansoprazole
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2008 · Synced Oct 21, 2026, 2:57 PM EDT
Completed No phase listed Observational

Treatment of Zollinger-Ellison Syndrome

NCT00001241
View directory record Official record
Conditions
Zollinger Ellison Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1989 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 2:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome

NCT02513784
View directory record Official record
Conditions
Esophageal Adenocarcinoma, Barrett's Esophagus, Reflux Esophagitis
Interventions
Chlorhexidine gluconate
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 21, 2026, 2:57 PM EDT
Completed Phase 3 Interventional Results available

A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)

NCT00527904
View directory record Official record
Conditions
Gastric Ulcer
Interventions
PN400 (VIMOVO), PN 400 (VIMOVO)
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 31, 2010 · Synced Oct 21, 2026, 2:57 PM EDT
Completed Phase 2Phase 3 Interventional

Rates of Gastric Ulcer by Endoscopy in Knee Osteoarthritis Patients Receiving LT-NS001 Versus Naprosyn®

NCT01063920
View directory record Official record
Conditions
Osteoarthritis
Interventions
LT-NS001, Naprosyn®
Drug
Lead sponsor
Logical Therapeutics
Industry
Eligibility
45 Years to 80 Years
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
65
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Oct 21, 2026, 2:57 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers

NCT00995410
View directory record Official record
Conditions
Aspirin-Associated Gastric Ulcers
Interventions
PA32540
Drug
Lead sponsor
POZEN
Industry
Eligibility
55 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 21, 2026, 2:57 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Feasibility Study of Phototherapy System to Treat H Pylori

NCT00306280
View directory record Official record
Conditions
Helicobacter Pylori
Interventions
Phototherapy
Device
Lead sponsor
LumeRx
Industry
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
3
States / cities
Boston, Massachusetts • Worcester, Massachusetts • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 20, 2006 · Synced Oct 21, 2026, 2:57 PM EDT
Recruiting Not applicable Interventional

Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Bleeding

NCT06188585
View directory record Official record
Conditions
Acute Gastrointestinal Bleeding
Interventions
UI-EWD, Conventional therapy
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
22 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
6
States / cities
New Haven, Connecticut • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 21, 2026, 2:57 PM EDT
Completed No phase listed Observational

Helicobacter Pylori Sample Collection Protocol Pre Therapy Subjects

NCT03060746
View directory record Official record
Conditions
Helicobacter Pylori Infection, Gastric Ulcer, Nausea, Abdominal Pain, Weight Loss, Stomach Ulcer, Loss of Appetite, Bloating
Interventions
Newly Diagnosed
Other
Lead sponsor
DiaSorin Inc.
Industry
Eligibility
22 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Mesa, Arizona • Mission Hills, California • Oxnard, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2021 · Synced Oct 21, 2026, 2:57 PM EDT
Recruiting Phase 4 Interventional

OPEN Versus InTact Capsule Proton Pump Inhibitors for the Treatment of Marginal Ulcers

NCT05799105
View directory record Official record
Conditions
Marginal Ulcer
Interventions
Omeprazole 40 milligrams
Drug
Lead sponsor
Stephen Firkins
Other
Eligibility
Not listed
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 21, 2026, 2:57 PM EDT